Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medtronic and Scil Technology have announced a development, licensing and supply agreement for the development of Scil's biologic rhGDF-5 dental regenerative technology for use in bone regeneration for dental implant placement and treatment of periodontal disease.
Subscribe to our email newsletter
Under this agreement, Scil Technology is primarily responsible for all R&D activities with Medtronic responsible for clinical trials, regulatory approvals and commercialization.
These regenerative biologics may offer new approaches to saving teeth in patients who are at risk for tooth loss due to periodontal disease and provide new options for other dental procedures for the placement of dental implants. These therapies would be alternative treatments to the traditional bridging procedures performed by dentists.
Pete Wehrly, senior vice president and president of Medtronic’s spinal and biologics business, said: “The partnership with Scil is a continuation of our strategy to expand our biologics portfolio. Scil’s therapies have the potential to offer our customers biologic solutions that will expand treatment options for their patients and offer new options for unmet needs in periodontal regeneration.”